Skip to Main Content

Paper Details

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Front Immunol
75
2021
Author NameAffiliation
Kim E NicholsSt. Jude Children's Research Hospital
  • 1 - 1

Datasets

Release 1.2